Neoantigen Targeted Therapies Market Report 2025

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $3.4 billion in 2024 to $4.72 billion in 2025 at a compound annual growth rate (CAGR) of 38.7%. The growth in the historic period can be attributed to advancements in genomic sequencing, immunotherapy evolution, understanding tumor immunology, clinical success of checkpoint inhibitors, molecular profiling advancements.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $16.01 billion in 2029 at a compound annual growth rate (CAGR) of 35.7%. The growth in the forecast period can be attributed to advancements in bioinformatics, precision medicine expansion, neoantigen vaccine development, therapeutic combination strategies, biomarker validation. Major trends in the forecast period include neoantigen resistance management, neoantigen-primed adoptive cell therapies, neoantigen-based combinatorial therapies, integration of real-world data, enhanced predictive models.

The anticipated growth in the neoantigen targeted therapies market is primarily attributed to the increasing incidence of cancer cases. This refers to the rise in new cancer cases within a specific population during a given period. Neoantigen targeted therapies, often administered in combination, are instrumental in treating various types of cancer. In 2022, the American Cancer Society reported a substantial increase in new cancer cases in the United States, reaching 1.9 million. Additionally, 609,360 deaths were attributed to cancer in the same year, underscoring the profound impact of the disease. Consequently, the surge in cancer incidence is a key driver propelling the growth of the neoantigen targeted therapies market.

The increasing emphasis on precision oncology is expected to drive the growth of the neoantigen-targeted therapies market in the future. Precision oncology is a cancer treatment approach that utilizes detailed genetic and molecular information about a patient's tumor to guide the selection of targeted therapies. This approach employs neoantigen-targeted therapies by leveraging advanced genomic analysis to identify unique neoantigens expressed by an individual’s cancer cells. The use of neoantigen-targeted therapies within precision oncology represents a strategy to tailor treatment to the specific genetic profile of each patient's tumor, providing a more personalized and effective treatment option. For instance, in March 2024, the Precision Oncology Clinical Trials & Statistics 2024 report published by Novotech, an Australia-based full-service clinical contract research organization focused on developing innovative therapeutics across all phases, noted that by November 2023, twelve treatments had received FDA approval for specific biomarker-selected indications, with six of these included in the NCCN guidelines. By the end of the year, 43% of the 217 FDA-approved oncology therapies were classified as precision oncology, with 78 of these therapies featuring DNA or NGS-detectable biomarkers, underscoring the growing importance of biomarker-driven treatments in cancer care. Thus, the rise in precision oncology is fueling the growth of the neoantigen-targeted therapies market.

Major companies in the neoantigen-targeted therapies market are pursuing a strategic partnership approach to personalize cancer therapies and address the challenges of existing immunotherapy in treating solid tumors. Strategic partnerships involve companies leveraging each other's strengths and resources to achieve mutual benefits and success. For example, in January 2023, BioNTech SE, a Germany-based biotechnology company, partnered with the Government of the United Kingdom to advance personalized mRNA cancer immunotherapies. This collaboration aims to deliver tailored treatments to as many as 10,000 patients by 2030, focusing on several critical areas, including the development of cancer immunotherapies, research on infectious disease vaccines, and the establishment of a research and development hub in Cambridge. The initiative will utilize the UK’s clinical trial infrastructure and health data resources to enhance patient recruitment and select trial sites for BioNTech’s mRNA treatments. The company plans to initiate its first clinical trials in the UK later this year, concentrating on cancer vaccines that could potentially be integrated into standard treatment protocols if proven effective.

Major companies in the neoantigen-targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs to tackle the challenges of existing immunotherapy in treating solid tumors. Strategic partnerships involve companies leveraging each other's strengths and resources for mutual benefit and success. For instance, in April 2023, Moderna, Inc., a US-based pharmaceutical and biotechnology company, collaborated with Merck & Co., Inc., a US-based pharmaceutical company, to launch mRNA-4157 (V940). This investigational individualized neoantigen therapy (INT) is designed to generate a tailored antitumor immune response based on the unique mutational signature of a patient's tumor. mRNA-4157 (V940) works by encoding up to 34 neoantigens to stimulate T cell responses, enhancing the body's ability to target and destroy tumor cells when combined with Merck’s immunotherapy KEYTRUDA. This combination aims to improve recurrence-free survival in patients with high-risk resected melanoma.

In January 2023, AstraZeneca plc, a UK-based pharmaceutical company, acquired Neogene Therapeutics Inc. for $200 million. This acquisition is intended to enhance AstraZeneca’s oncology portfolio, with a particular focus on developing transformative T-cell receptor (TCR) therapies that target neoantigens in solid tumors. Neogene's expertise in next-generation TCR-T therapies is expected to complement AstraZeneca's existing capabilities in the oncology field, allowing the company to advance its cancer treatment initiatives. Neogene Therapeutics Inc. is a US-based biotechnology company that specializes in neoantigen-targeted therapies.

Major companies operating in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics Plc, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

North America was the largest region in the neoantigen targeted therapies market in 2024. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neoantigen targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Neoantigen-targeted therapies represent a precision medicine approach focused on leveraging neoantigens within cancer cells. Neoantigens, distinct antigens arising from genetic abnormalities in cancer cells, become the target for harnessing the body's immune system to specifically identify and combat cancer.

These therapies fall into two main categories, monotherapy and combination therapy. Monotherapy involves utilizing a single medicine or therapeutic approach to address the disease. Immunotherapy options encompass DNA or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies, with applications spanning colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. Administration routes include intradermal, intravenous, and subcutaneous, while applications extend to medical research institutions, hospitals, clinics, and other healthcare settings.

The neoantigen targeted therapies market research report is one of a series of new reports that provides neoantigen targeted therapies market statistics, including the neoantigen targeted therapies industry global market size, regional shares, competitors with a neoantigen targeted therapies market share, detailed neoantigen targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. This neoantigen targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.